YAP, but Not RSPO-LGR4/5, Signaling in Biliary Epithelial Cells Promotes a Ductular Reaction in Response to Liver Injury.


Journal

Cell stem cell
ISSN: 1875-9777
Titre abrégé: Cell Stem Cell
Pays: United States
ID NLM: 101311472

Informations de publication

Date de publication:
03 07 2019
Historique:
received: 01 06 2018
revised: 29 01 2019
accepted: 04 04 2019
pubmed: 14 5 2019
medline: 22 8 2020
entrez: 14 5 2019
Statut: ppublish

Résumé

Biliary epithelial cells (BECs) form bile ducts in the liver and are facultative liver stem cells that establish a ductular reaction (DR) to support liver regeneration following injury. Liver damage induces periportal LGR5+ putative liver stem cells that can form BEC-like organoids, suggesting that RSPO-LGR4/5-mediated WNT/β-catenin activity is important for a DR. We addressed the roles of this and other signaling pathways in a DR by performing a focused CRISPR-based loss-of-function screen in BEC-like organoids, followed by in vivo validation and single-cell RNA sequencing. We found that BECs lack and do not require LGR4/5-mediated WNT/β-catenin signaling during a DR, whereas YAP and mTORC1 signaling are required for this process. Upregulation of AXIN2 and LGR5 is required in hepatocytes to enable their regenerative capacity in response to injury. Together, these data highlight heterogeneity within the BEC pool, delineate signaling pathways involved in a DR, and clarify the identity and roles of injury-induced periportal LGR5+ cells.

Identifiants

pubmed: 31080135
pii: S1934-5909(19)30154-7
doi: 10.1016/j.stem.2019.04.005
pii:
doi:

Substances chimiques

3,5-diethoxycarbonyl-1,4-dihydrocollidine 0
Adaptor Proteins, Signal Transducing 0
Axin Protein 0
Axin2 protein, mouse 0
Cell Cycle Proteins 0
LGR4 protein, mouse 0
Lgr5 protein, mouse 0
Pyridines 0
RSPO1 protein, mouse 0
Receptors, G-Protein-Coupled 0
Thrombospondins 0
YAP-Signaling Proteins 0
Yap1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-53.e10

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Lara Planas-Paz (L)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Tianliang Sun (T)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Monika Pikiolek (M)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Nadire R Cochran (NR)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Sebastian Bergling (S)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Vanessa Orsini (V)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Zinger Yang (Z)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Frederic Sigoillot (F)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Jasna Jetzer (J)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Maryam Syed (M)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Marilisa Neri (M)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Sven Schuierer (S)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Lapo Morelli (L)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Philipp S Hoppe (PS)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Wibke Schwarzer (W)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Carlos M Cobos (CM)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; Hospital Aleman, Buenos Aires, Argentina.

John L Alford (JL)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Le Zhang (L)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Rachel Cuttat (R)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Annick Waldt (A)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Nicole Carballido-Perrig (N)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Florian Nigsch (F)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Bernd Kinzel (B)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Thomas B Nicholson (TB)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Yi Yang (Y)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Xiaohong Mao (X)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Luigi M Terracciano (LM)

Institute for Pathology, University Hospital Basel, Basel, Switzerland.

Carsten Russ (C)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

John S Reece-Hoyes (JS)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Caroline Gubser Keller (C)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Andreas W Sailer (AW)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Tewis Bouwmeester (T)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Linda E Greenbaum (LE)

Novartis Institutes for Biomedical Research, Novartis Pharma AG, East Hanover, NJ, USA.

Jesse J Lugus (JJ)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Feng Cong (F)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Gregory McAllister (G)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Gregory R Hoffman (GR)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA, USA.

Guglielmo Roma (G)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.

Jan S Tchorz (JS)

Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland. Electronic address: jan.tchorz@novartis.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH